Search Result

Results for "

PDE5 inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (12) Autophagy (8) Bacterial (4) Beta-secretase (1) Cholinesterase (ChE) (1) Drug Metabolite (1) EGFR (1) Endogenous Metabolite (12) Glucocorticoid Receptor (2) GPR35 (1) HDAC (2) Histamine Receptor (3) Isotope-Labeled Compounds (9) Na+/H+ Exchanger (NHE) (1) NF-κB (1) NO Synthase (4) Phosphodiesterase (PDE) (97) PPAR (2) RSV (5) Wnt (3) β-catenin (2)
By Research Areas:	Cancer (23) Cardiovascular Disease (36) Endocrinology (26) Inflammation/Immunology (28) Metabolic Disease (14) Neurological Disease (17)

100

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153766

PDE5-IN-9	Phosphodiesterase (PDE)	Cardiovascular Disease
PDE5-IN-9 (Compound 59) is a *PDE5* inhibitor (IC₅₀: 11.2 μM). PDE5-IN-9 shows interaction with Gln 817, Tyr 612, and Ala 767 amino acid residues. PDE5-IN-9 can be used for research of cardiovascular disease .

HY-149661

PDE5-IN-11	Phosphodiesterase (PDE)	Cardiovascular Disease
PDE5-IN-11 is a potent inhibitor of *PDE5* with an IC₅₀ of 40 nM. PDE5-IN-11 also inhibits PDE4 and PDE6 with IC₅₀s of 1.78 and 0.09 μM, respectively .

HY-155687

PDE5-IN-10	Phosphodiesterase (PDE)	Neurological Disease
PDE5-IN-10 (compound 4b) is a potent *PDE5* inhibitor with an IC₅₀ of 20 nM. PDE5-IN-10 improves in vitro microsomal stability (t_1/2 = 44.6 min) as well as excellent efficacy in restoring long-term potentiation. PDE5-IN-10 can be used for Alzheimer’s disease (AD) research .

HY-90009D

(6S,12aR)-Tadalafil Tadalafil EP Impurity C; (6S,12aR)-IC-351	Phosphodiesterase (PDE)	Metabolic Disease
(6S,12aR)-Tadalafil (Tadalafil EP Impurity C) is a highly potent *PDE5* inhibitor with an IC₅₀ value of 5 nM and has blood pressure lowering activity .

HY-18252B

(R)-Avanafil (R)-TA1790	Phosphodiesterase (PDE)	Endocrinology
(R)-Avanafil ((R)-TA1790) is a selective PDE5 inhibitor (IC₅₀: 5.2 nM). (R)-Avanafil can be used for research of erectile dysfunction .

HY-131710

PDE5-IN-3	Phosphodiesterase (PDE) EGFR Wnt Apoptosis	Cancer
PDE5-IN-3 (compound 11j) is a potent *PDE5* inhibitor with an IC₅₀ of 1.57 nM. PDE5-IN-3 shows moderate EGFR inhibition with IC₅₀ of 5.827 µM. PDE5-IN-3 significantly inhibits the Wnt/β-catenin pathway (IC₅₀=1286.96 ng/mL). PDE5-IN-3 induces the intrinsic apoptotic mitochondrial pathway in HepG2 cells. PDE5-IN-3 has strong antitumor activity .

HY-128060

PDE5-IN-42	Phosphodiesterase (PDE)	Cardiovascular Disease
PDE5-IN-42 (Compound 42) is a potent and orally active *PDE5* inhibitor with an IC₅₀ of 0.04 nM. PDE5-IN-42 maintains selectivity over PDE6 and PDE11 .

HY-161290

PDE5-IN-12	Phosphodiesterase (PDE)	Cardiovascular Disease
PDE5-IN-12 (compound 4h) is a potent phosphodiesterase-5 (PDE-5) inhibitor with an IC₅₀ of 22 nM. PDE5-IN-12 shows anti-proliferative effects against the aortic cell line .

HY-147990

PDE5-IN-5	Phosphodiesterase (PDE)	Cancer
PDE5-IN-5 (Compound 11) is a potent, selective phosphodiesterase 5 (PDE5) inhibitor with an IC₅₀ of 2.0 nM .

HY-147991

PDE5/HDAC-IN-1	Phosphodiesterase (PDE) HDAC Apoptosis	Cancer
PDE5/HDAC-IN-1 (Compound 26) is a potent phosphodiesterase 5 (PDE5) and HDAC inhibitor with IC₅₀ values of 46.3 nM and 14.5 nM, respectively. PDE5/HDAC-IN-1 induces cell apoptosis and shows anticancer activities .

HY-124310

PDE5-IN-6c	Others	Neurological Disease
PDE5-IN-6c is a potent and selective phosphodiesterase 5A1 (PDE5A1) inhibitor with the potential to inhibit Alzheimer's disease (AD). PDE5-IN-6c exhibits an excellent in vitro IC50 (0.056 nM), demonstrating its potent inhibitory activity. PDE5-IN-6c has improved water solubility, making it a more attractive drug candidate .

HY-142059

PDE5-IN-4	Phosphodiesterase (PDE)	Cardiovascular Disease Metabolic Disease
PDE5-IN-4 is a phosphodiesterase 5 inhibitor. PDE5-IN-4 can be used for the research of acute myocardial infarction and damage caused by reperfusion, gastrointestinal diseases, damage caused by diabetes, and liver failure .

HY-19420

UK 357903	Phosphodiesterase (PDE)	Others
UK 357903 is a selective inhibitor for phosphodiesterase 5 (PDE5), with IC₅₀s of 1.7 and 714 nM, for *PDE5* and PDE6. UK 357903 exhibits vasodilatory effects on the mesenteric and hindlimb vascular beds, and is potential for ameliorating erectile dysfunction .

HY-114303

CM-675	Phosphodiesterase (PDE) HDAC	Neurological Disease
CM-675 is a dual phosphodiesterase 5 (PDE5) and class I histone deacetylases-selective inhibitor, with IC₅₀ values of 114 nM and 673 nM for PDE5 and HDAC1, respectively. CM-675 has potential to treat Alzheimer’s disease .

HY-101826

ER21355	Phosphodiesterase (PDE)	Cancer
ER21355 is an inhibitor of phosphodiesterase 5 (PDE5), used for treatment of prostatic diseases.

HY-90009A

Tadalafil 5+ Cited Publications IC-351	Phosphodiesterase (PDE) Apoptosis	Cardiovascular Disease Cancer
Tadalafil (IC-351) is a *PDE5* inhibitor with an IC₅₀ value of 1.8 nM.

HY-W011336

PDE5-IN-7	Phosphodiesterase (PDE)	Others
PDE5-IN-7 (compound 8) is a selective phosphodiesterase 5 (PDE 5) inhibitor with an IC₅₀ value of 5 nM, while an IC₅₀ of 300 nM for PDE 1 .

HY-112704

PDE5-IN-2	Phosphodiesterase (PDE)	Cardiovascular Disease
PDE5-IN-2 is a potent, highly selective, and orally active *PDE5* inhibitor, with an IC₅₀ of 0.31 nM, less potently inhibits PDE2A, PDE10A, PDE4D2, and PDE6C, with IC₅₀s of 106, 46, 43, 1.2 nM, respectively. Anti-pulmonary arterial hypertension activity .

HY-15025A

Sildenafil citrate 5+ Cited Publications UK-92480 citrate	Phosphodiesterase (PDE) Autophagy Apoptosis Bacterial	Cardiovascular Disease Cancer
Sildenafil citrate is a potent phosphodiesterase type 5 (PDE5) inhibitor with IC₅₀ of 5.22 nM.

HY-123210

Lodenafil Hydroxyhomosildenafil	Phosphodiesterase (PDE)	Endocrinology
Lodenafil is a potent phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED) .

HY-145000

N-Desalkyludenafil	Drug Metabolite	Endocrinology
N-Desalkyludenafil is a metabolite of Udenafil. Udenafil is a PDE5 inhibitor used for the research of the erectile dysfunction .

HY-15025

Sildenafil 5+ Cited Publications UK-92480	Phosphodiesterase (PDE) Autophagy Apoptosis Bacterial	Cardiovascular Disease Cancer
Sildenafil (UK-92480) is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC₅₀ of 5.22 nM.

HY-119611A

Thioquinapiperifil dihydrochloride KF31327	Phosphodiesterase (PDE)	Metabolic Disease Endocrinology
Thioquinapiperifil dihydrochloride (KF31327), a potent, selective and non-competitive phosphodiesterase-5 (PDE-5, IC₅₀ of 0.074 nM) inhibitor, is used for sexual enhancement study .

HY-119611

Thioquinapiperifil KF31327 free base	Phosphodiesterase (PDE)	Metabolic Disease Endocrinology
Thioquinapiperifil (KF31327 free base), a potent, selective and non-competitive phosphodiesterase-5 (PDE-5, IC₅₀ of 0.074 nM) inhibitor, is used for sexual enhancement study .

HY-117605

N-Desmethyl Sildenafil Desmethylsildenafil; UK-103,320	Phosphodiesterase (PDE)	Cardiovascular Disease
N-Desmethyl Sildenafil (Desmethylsildenafil) is a major metabolite of Sildenafil. Sildenafil is a potent phosphodiesterase type 5 (PDE5) inhibitor .

HY-13927

Acetildenafil	Phosphodiesterase (PDE)	Cardiovascular Disease Cancer
Acetildenafil is a Sildenafil (HY-15025) analogue, a phosphodiesterase 5 (PDE5) inhibitor. Acetildenafil can be isolated from herbal products .

HY-107191

Sildenafil Mesylate	Phosphodiesterase (PDE)	Cancer
Sildenafil Mesylate is an orally active and selective phosphodiesterase type 5 (PDE5) inhibitor. Sildenafil Mesylate can be used in studies of erectile dysfunction and cancer .

HY-132002

Dimethylsildenafil	Others	Cardiovascular Disease
Dimethylsildenafil is a derivative of Sildenafil (HY-15025). Sildenafil is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC₅₀ of 5.22 nM .

HY-108045

Lodenafil carbonate	Phosphodiesterase (PDE)	Endocrinology
Lodenafil carbonate, a dimer that acts as a proagent delivering Lodenafil in vivo, is an orally active phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED) .

HY-90009B

12-epi-Tadalafil 12-epi-IC-351	Phosphodiesterase (PDE)	Cardiovascular Disease
12-epi-Tadalafil is a *PDE5* inhibitor (IC₅₀: 0.09 μM). 12-epi-Tadalafil can be used for research of cardiovascular diseases .

HY-90009AR

Tadalafil (Standard) IC-351 (Standard)	Phosphodiesterase (PDE) Apoptosis	Cardiovascular Disease Cancer
Tadalafil (Standard) is the analytical standard of Tadalafil. This product is intended for research and analytical applications. Tadalafil (IC-351) is a *PDE5* inhibitor with an IC₅₀ value of 1.8 nM.

HY-100650

Carbodenafil	Phosphodiesterase (PDE)	Others
Carbodenafil is a Sildenafil (UK-92480) related compound found in health foods. Sildenafil is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC50 of 5.22 nM .

HY-14841

Gisadenafil UK-369003	Phosphodiesterase (PDE)	Neurological Disease
Gisadenafil (UK-369003) is a specific, orally active phosphodiesterase 5 (PDE5) inhibitor with an IC₅₀ of 3.6 nM and prevents degradation of cyclic guanosine monophosphate (cGMP) .

HY-123210R

Lodenafil (Standard)	Phosphodiesterase (PDE)	Endocrinology
Lodenafil (Standard) is the analytical standard of Lodenafil. This product is intended for research and analytical applications. Lodenafil is a potent phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED) .

HY-12318

IBMX Maximum Cited Publications 39 Publications Verification 3-Isobutyl-1-methylxanthine; Isobutylmethylxanthine	Phosphodiesterase (PDE)	Inflammation/Immunology
IBMX is a broad-spectrum phosphodiesterase (PDE) inhibitor, with IC₅₀s of 6.5, 26.3 and 31.7 μM for PDE3, PDE4 and *PDE5*, respectively.

HY-N0014

Icariin 10+ Cited Publications Ieariline	Phosphodiesterase (PDE) PPAR Autophagy	Cardiovascular Disease Inflammation/Immunology Cancer
Icariin is a flavonol glycoside. Icariin inhibits *PDE5* and PDE4 activities with IC₅₀s of 432 nM and 73.50 μM, respectively. Icariin also is a PPARα activator.

HY-128593

TPN171	Phosphodiesterase (PDE)	Cardiovascular Disease
TPN171 is a potent, selective and oral bioavailable inhibitor of phosphodiesterase type 5 (PDE5) with an IC₅₀ of 0.62 nM, being developed for the treatment of pulmonary arterial hypertension (PAH) .

HY-108619

Gisadenafil besylate UK 369003-26	Phosphodiesterase (PDE)	Neurological Disease
Gisadenafil besylate (UK 369003-26) is a specific, orally active phosphodiesterase 5 (PDE5) inhibitor with an IC₅₀ of 3.6 nM and prevents degradation of cyclic guanosine monophosphate (cGMP) .

HY-15025AS

Sildenafil citrate-d8 UK-92480 citrate-d₈	Phosphodiesterase (PDE) Apoptosis Bacterial Autophagy	Cardiovascular Disease
Sildenafil (citrate)-d₈ is the deuterium labeled Sildenafil citrate[1]. Sildenafil citrate is a potent phosphodiesterase type 5 (PDE5) inhibitor with IC50 of 5.22 nM.

HY-18253

Udenafil DA8159	Phosphodiesterase (PDE)	Endocrinology Cancer
Udenafil (DA8159) is a potent, selective and orally active phosphodiesterase type 5 (PDE5) inhibitor. Udenafil also inhibits cGMP hydrolysis and can be used for erectile dysfunction research .

HY-15025S

Sildenafil-d3 UK-92480-d₃	Phosphodiesterase (PDE)	Cardiovascular Disease Cancer
Sildenafil-d₃ is deuterium labeled Sildenafil-d₃. Sildenafil (UK-92480) is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC50 of 5.22 nM.

HY-117109

Amino Tadalafil	Phosphodiesterase (PDE)	Metabolic Disease
Amino Tadalafil is an analog of Tadalafil. Tadalafil is a potent inhibitor of phosphodiesterase 5 (PDE5) with applications in several conditions, including erectile dysfunction, pulmonary arterial hypertension, and lower urinary tract dysfunction.

HY-116808

TPN729	Phosphodiesterase (PDE)	Neurological Disease
TPN729 is a selective phosphodiesterase type 5 (PDE5) inhibitor with an IC₅₀ value of 2.28 nM. TPN729 affects erectile function and it can be used for the research of erectile dysfunction .

HY-15025AR

Sildenafil citrate (Standard) UK-92480 citrate (Standard)	Phosphodiesterase (PDE) Autophagy Apoptosis Bacterial	Cardiovascular Disease Cancer
Sildenafil (citrate) (Standard) is the analytical standard of Sildenafil (citrate). This product is intended for research and analytical applications. Sildenafil citrate is a potent phosphodiesterase type 5 (PDE5) inhibitor with IC₅₀ of 5.22 nM.

HY-105349

T-0156	Phosphodiesterase (PDE)	Neurological Disease
T-0156 is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor. T-0156 specifically inhibits the hydrolysis of cyclic guanosine monophosphate (cGMP) by PDE5 in a competitive manner (IC₅₀=0.23 nM). T-0156 inhibits PDE6 (IC₅₀=56 nM) and has low potencies against PDE1, PDE2, PDE3, and PDE4 (IC₅₀>10 μM). T-0156 enhances the nitric oxide (NO)/cGMP pathway .

HY-15025S1

Sildenafil-d8 UK-92480-d₈	Isotope-Labeled Compounds Phosphodiesterase (PDE) Autophagy Apoptosis	Cardiovascular Disease Cancer
Sildenafil-d₈ is the deuterium labeled Sildenafil. Sildenafil (UK-92480) is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC50 of 5.22 nM[1][2].

HY-18252

Avanafil 1 Publications Verification TA1790	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite	Cardiovascular Disease Endocrinology
Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-18252A

Avanafil dibenzenesulfonate TA1790 dibenzenesulfonate	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite	Cardiovascular Disease Endocrinology
Avanafil (TA-1790) dibenzenesulfonate is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis .

HY-116808B

TPN729MA TPN729 maleate	Phosphodiesterase (PDE)	Neurological Disease
TPN729MA (TPN729 maleate) is a selective phosphodiesterase type 5 (PDE5) inhibitor with an IC₅₀ value of 2.28 nM. TPN729MA affects erectile function and it can be used for the research of erectile dysfunction .

HY-164685

T-0156 free base	Phosphodiesterase (PDE)	Neurological Disease
T-0156 free base is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor. T-0156 free base specifically inhibits the hydrolysis of cyclic guanosine monophosphate (cGMP) by PDE5 in a competitive manner (IC₅₀=0.23 nM). T-0156 free base inhibits PDE6 (IC₅₀=56 nM) and has low potencies against PDE1, PDE2, PDE3, and PDE4 (IC₅₀>10 μM). T-0156 free base enhances the nitric oxide (NO)/cGMP pathway .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0014

Icariin Maximum Cited Publications 12 Publications Verification Ieariline	Cardiovascular Disease Flavonols Structural Classification Classification of Application Fields Anti-aging Source classification Plants Monophenols Flavonoids Phenols Epimedium brevicornu Maxim. Berberidaceae Inflammation/Immunology Disease Research Fields Cancer	Phosphodiesterase (PDE) PPAR Autophagy
Icariin is a flavonol glycoside. Icariin inhibits *PDE5* and PDE4 activities with IC₅₀s of 432 nM and 73.50 μM, respectively. Icariin also is a PPARα activator.

HY-18252

Avanafil 1 Publications Verification TA1790	Cardiovascular Disease Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Endocrinology	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-N1860

3-O-Methylquercetin	Rhamnus nakaharai (Hayata) Hayata Structural Classification Flavonoids Classification of Application Fields Flavones Plants Rhamnaceae Inflammation/Immunology Disease Research Fields	Phosphodiesterase (PDE)
3-O-Methylquercetin (3-MQ) is a major component from the plant Rhamnus nakaharai and has antiviral activity and potential antiasthmatic efficacy. 3-O-Methylquercetin inhibits total cAMP and cGMP-phosphodiesterase (PDE). The IC₅₀ values of 3-O-Methylquercetin (3-MQ) against PDE1-PDE5 are in the range of 1.6-86.9 μM. 3-O-Methylquercetin is a non-competitive inhibitor of PDE2 and a competitive inhibitor of PDE4 .

HY-A0027

Fenspiride hydrochloride	Classification of Application Fields Disease Research Fields Endocrinology	Histamine Receptor Phosphodiesterase (PDE)
Fenspiride, an orally active non-steroidal antiinflammatory agent, is an antagonist of H1-histamine receptor. Fenspiride inhibites phosphodiesterase 3 (PDE3), phosphodiesterase 4 (PDE4) and phosphodiesterase 5 (PDE5) activities with -log IC₅₀ values of 3.44, 4.16 and approximately 3.8, respectively. Fenspiride can be used for the research of respiratory diseases .

HY-N2284

Sophoflavescenol	Flavonols Flavonoids Classification of Application Fields Leguminosae Source classification Phenols Polyphenols Plants Sophora flavescens Aiton Disease Research Fields Cancer	Cholinesterase (ChE) Beta-secretase Phosphodiesterase (PDE)
Sophoflavescenol is a prenylated flavonol, which shows great inhibitory activity with IC₅₀ of 0.013 μM against Phosphodiesterase 5 (PDE5), and also inhibits RLAR, HRAR, AGE, BACE1, AChE and BChE with IC₅₀s of 0.30 µM, 0.17 µM, 17.89 µg/mL, 10.98 µM, 8.37 µM and 8.21 µM, respectively.

HY-B0442

Vardenafil 2 Publications Verification	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology	Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B0442A

Vardenafil hydrochloride 2 Publications Verification	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology	Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-18252A

Avanafil dibenzenesulfonate TA1790 dibenzenesulfonate	Cardiovascular Disease Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Endocrinology	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (TA-1790) dibenzenesulfonate is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis .

HY-N6256

Ilexsaponin B2	Cardiovascular Disease Aquifoliaceae Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Ilex pubescens Hook. et Arn. Plants Disease Research Fields	Phosphodiesterase (PDE)
Ilexsaponin B2 is a saponin isolated from the root of Ilex pubescens Hook. et Arn. Ilexsaponin B2 is a potent phosphodiesterase 5 (PDE5) and PDEI inhibitor with IC₅₀ values of 48.8 μM and 477.5 μM, respectively .

HY-N0014R

Icariin (Standard) Ieariline (Standard)	Cardiovascular Disease Structural Classification Classification of Application Fields Anti-aging Source classification Plants Flavonoids Phenols Epimedium brevicornu Maxim. Berberidaceae Inflammation/Immunology Disease Research Fields Cancer	Phosphodiesterase (PDE) PPAR Autophagy
Icariin (Standard) is the analytical standard of Icariin. This product is intended for research and analytical applications. Icariin is a flavonol glycoside. Icariin inhibits *PDE5* and PDE4 activities with IC₅₀s of 432 nM and 73.50 μM, respectively. Icariin also is a PPARα activator.

HY-B0442C

Vardenafil dihydrochloride	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology	Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM respectively, while IC₅₀s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^- .

HY-B0442B

Vardenafil hydrochloride trihydrate 2 Publications Verification	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology	Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B0442R

Vardenafil (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil (Standard) is the analytical standard of Vardenafil. This product is intended for research and analytical applications. Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B0442BR

Vardenafil hydrochloride trihydrate (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil (hydrochloride trihydrate) (Standard) is the analytical standard of Vardenafil (hydrochloride trihydrate). This product is intended for research and analytical applications. Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-N10156

1,3,5-Trihydroxy-4-prenylxanthone	Flavonoids Leguminosae Source classification Plants Other Flavonoids Erythrina variegata Linn.	Na+/H+ Exchanger (NHE) Phosphodiesterase (PDE) NO Synthase
1,3,5-Trihydroxy-4-prenylxanthone is a Na ⁺/H ⁺ exchange system (Na+/H+ Exchanger (NHE)) inhibitor with a minimum inhibitory concentration of 10 μg/mL . 1,3,5-Trihydroxy-4-prenylxanthone is a phosphodiesterase type 5 (PDE5) (Phosphodiesterase (PDE)) inhibitor with an IC₅₀ value of 3.0 μM . 1,3,5-Trihydroxy-4-prenylxanthone inhibits Lipopolysaccharide (LPS) (Lipopolysaccharides (HY-D1056))-induced NO production in RAW264.7 macrophages, and has anti-inflammatory activities .

HY-122942

Moracin M	Structural Classification Classification of Application Fields Source classification Phenols Polyphenols Plants Moraceae Endogenous metabolite Inflammation/Immunology Disease Research Fields Morus alba Linn.	Phosphodiesterase (PDE) Endogenous Metabolite NF-κB Autophagy
Moracin M is a phenolic component that can be isolated from Mori Cortex, is a potent phosphodiesterase-4 (PDE4) inhibitor with IC₅₀ values of 2.9, 4.5, >40, and >100 μM for PDE4D2, PDE4B2, PDE5A1, and PDE9A2, respectively. Moracin M has anti-inflammatory activity .

Cat. No.	Product Name	Chemical Structure

HY-15025S

Sildenafil-d3
Sildenafil-d₃ is deuterium labeled Sildenafil-d₃. Sildenafil (UK-92480) is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC50 of 5.22 nM.

HY-90009S

Tadalafil-d3
Tadalafil-d₃ is the deuterium labeled Nortadalafil. Nortadalafil is demethyl Tadalafil, which is a PDE5 inhibitor, currently marketed in pill form for treating erectile dysfunction (ED) under the name Cialis; and under the name Adcirca for the treatment of pulmonary arterial hypertension.

HY-15025S2

Sildenafil-d3-1
Sildenafil-d3-1 (UK-92480-d3-1) is deuterium labeled Sildenafil-d₃. Sildenafil (UK-92480) is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC₅₀ of 5.22 nM.

HY-15025AS

Sildenafil citrate-d8
Sildenafil (citrate)-d₈ is the deuterium labeled Sildenafil citrate[1]. Sildenafil citrate is a potent phosphodiesterase type 5 (PDE5) inhibitor with IC50 of 5.22 nM.

HY-15025S1

Sildenafil-d8
Sildenafil-d₈ is the deuterium labeled Sildenafil. Sildenafil (UK-92480) is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC50 of 5.22 nM[1][2].

HY-90009AS

Tadalafil-13C2,d3
Tadalafil- ¹³C₂,d₃ is ¹³C and deuterated labeled Tadalafil (HY-90009A). Tadalafil (IC-351) is a *PDE5* inhibitor with an IC₅₀ value of 1.8 nM.

HY-18252S1

Avanafil-13C5,15N,d2

Avanafil- ¹³C₅, ¹⁵N,d₂ is ¹⁵N and deuterated labeled Avanafil (HY-18252). Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-117605S

N-Desmethyl Sildenafil-d8
N-Desmethyl Sildenafil-d₈ is the deuterium labeled N-Desmethyl Sildenafil (HY-117605). N-Desmethyl Sildenafil is a major metabolite of Sildenafil. Sildenafil is a potent phosphodiesterase type 5 (PDE5) inhibitor[1][2][3].

HY-18253S

Udenafil-d7
Udenafil-d₇ is the deuterium labeled Udenafil. Udenafil (DA8159) is a potent, selective and orally active phosphodiesterase type 5 (PDE5) inhibitor. Udenafil also inhibits cGMP hydrolysis and can be used for erectile dysfunction research[1][2].

HY-15455S2

Roflumilast-d3
Roflumilast-d₃ is deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells.

HY-15455S

Roflumilast-d4
Roflumilast-d₄ is the deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells[1][2].

HY-15455S1

Roflumilast-d4 N-Oxide
Roflumilast-d₄ N-Oxide is the deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells[1][2].

HY-B0442S

Vardenafil-d5

Vardenafil-d₅ is deuterium labeled Vardenafil. Vardenafil is a selective, orally active, potent inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil shows selectivity over PDE1 (180 nM), PDE6 (11 nM), PDE2, PDE3, and PDE4 (>1000 nM). Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil can be used for the research of erectile dysfunction[1][2].

HY-A0027AS

Fenspiride-d5

Fenspiride-d₅ is the deuterium labeled Fenspiride. Fenspiride, an orally active non-steroidal antiinflammatory agent, is an antagonist of H1-histamine receptor. Fenspiride inhibites phosphodiesterase 3 (PDE3), phosphodiesterase 4 (PDE4) and phosphodiesterase 5 (PDE5) activities with -log IC50 values of 3.44, 4.16 and approximately 3.8, respectively. Fenspiride can be used for the research of respiratory diseases[1][2][3].

HY-B0442AS

Vardenafil-d5 hydrochloride

Vardenafil-d₅ hydrochloride is deuterated labeled Vardenafil hydrochloride (HY-B0442A). Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks